Back

EDEM2 is new therapeutic target for improving diabetes-induced cardiomyopathy by regulating DSG2

1 September 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Pathophysiology and mechanisms in chronic heart failure (2) Experimental Heart Failure ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Miss Jiayan Zhang

University of Manchester, Manchester (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
Global longitudinal strain evolution after cancer treatment in breast cancer females
Doctor N. Amdouni Moussi (Tunis, TN)
Abstract Slides Video
Presentation thumbnail
Impact of the 2022 ESC/ERS guidelines on diagnosing pulmonary hypertension in heart failure with reduced ejection fraction patients undergoing elective right heart catheterization
Mr F. Sawczak (Poznan, PL)
Abstract Slides Video
Presentation thumbnail
Sex differences in functional capacity and haemodynamic features in patients with dilated cardiomyopathy (DCM) with similar clinical characteristics
Doctor F. Giardino (Naples, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Pathophysiology and mechanisms in chronic heart failure (2)

The Event

Event poster

ESC Congress 2025

1 September 2025 11:15 CET
You may be interested in
thumbnail
Congress Presentation
EDEM2 is a new therapeutic target for improving diabetes-induced cardiomyopathy by regulating DSG2
thumbnail
Congress Presentation
The role of EDEM2 in the heart under metabolic stress
thumbnail
Congress Presentation
Mammalian Diaphanous-related formin 1 (mDia1) inducing diabetic cardiomyopathy by regulating metabolic reprogramming

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources